Year: 2021

NextCure and Collaborators Provide Clinical and Research Updates on NC318 and NC410 Candidates at Society for Immunotherapy of Cancer Annual Meeting

BELTSVILLE, Md., Nov. 13, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing...

Outlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual Conference

- NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data - Data support planned...

Helius Medical Technologies, Inc. Announces Closing of $11.1 Million Underwritten Public Offering of Common Stock Including Full Exercise of Over-Allotment Option

NEWTOWN, Pa., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech...

error: Content is protected !!